The long-standing shortage of popular weight-loss and diabetes drugs Ozempic and Wegovy has officially ended, according to the FDA. This development marks a significant moment for the pharmaceutical industry, as it could intensify competition among weight loss drug manufacturers. Shares of Hims & Hers experienced a sharp decline of 26% following the announcement that semaglutide, the active ingredient in these drugs, is no longer in short supply. Novo Nordisk, the maker of semaglutide, now faces new challenges as the conclusion of the shortage may impact smaller compounders who previously filled the gap. Meanwhile, Pfizer’s CEO has taken on the role of PhRMA’s new chair, signaling potential shifts in pharmaceutical leadership and strategy. — news from Axios
